<DOC>
	<DOC>NCT00663442</DOC>
	<brief_summary>Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week, parent report measures, clinical interviews, and safety assessments are conducted. Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype will predict response</brief_summary>
	<brief_title>Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>617 DSM IV criteria for ADHD Parents willing to complete measures Mental retardation psychoses seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>ADHD</keyword>
	<keyword>side effects</keyword>
	<keyword>sleep</keyword>
	<keyword>dopamine</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>